Hydroxyprogesterone heptanoate benzilic acid hydrazone
Clinical data
Other namesHydroxyprogesterone heptanoate benziloylhydrazone; OHPHBH; Hydroxyprogesterone enanthate benzilic acid hydrazone; 17α-Hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone
Routes of
administration		Intramuscular injection
Drug classProgestin; Progestogen; Progestogen ester
Identifiers
CAS Number
Chemical and physical data
FormulaC42H54N2O5
Molar mass666.903 g·mol−1
3D model (JSmol)
  • O(C(CCCCCC)=O)[C@@](C(C)=O)1CC[C@]([H])2[C@@]([H])3CCC4=C/C(/CC[C@]4(C)[C@@]3([H])CC[C@@]21C)=N/N([H])C(C(O[H])(C1=CC=CC=C1)C1=CC=CC=C1)=O
  • InChI=KECPQDDETDYRFU-HXKOVYISSA-N
  • Key:1S/C42H54N2O5/c1-5-6-7-14-19-37(46)49-41(29(2)45)27-24-36-34-21-20-32-28-33(22-25-39(32,3)35(34)23-26-40(36,41)4)43-44-38(47)42(48,30-15-10-8-11-16-30)31-17-12-9-13-18-31/h8-13,15-18,28,34-36,48H,5-7,14,19-27H2,1-4H3,(H,44,47)/b43-33+/t34-,35+,36+,39+,40+,41+/m1/s1

Hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), also known as 17α-hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone, is a progestin medication which was never marketed.[1][2] It is the C3 benzilic acid hydrazone of hydroxyprogesterone heptanoate (OHPH).[1][2] The medication has a longer duration of action than OHPH when administered by subcutaneous injection in animals.[1][2]

See also

References

  1. ^ a b c Ralph I. Dorfman (3 February 2016). Bioassay. Elsevier. pp. 252–. ISBN 978-1-4832-7276-4.
  2. ^ a b c Gleason CH, Parker JM (1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate". Endocrinology. 65 (3): 508–511. doi:10.1210/endo-65-3-508. ISSN 0013-7227. PMID 13828402.



Categories